Article Details
Retrieved on: 2023-01-12 01:17:02
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Hayakawa, head of targeted protein degradation at Astellas, gives us insights into the state of the biopharma industry in 2023.
Article found on: www.labiotech.eu
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here